case_images: PMC10578406_01
case_images: Schematic overview showing theoretical time- and drug exposure-dependent effects of the once-weekly subcutaneously administered glucagon-like peptide 1 receptor agonist (GLP-1RA) semaglutide (top) and the once-daily subcutaneously administered GLP-1RA liraglutide (bottom), respectively, on bile acid diarrhea (BAD) symptoms in a 62-year-old man with BAD. Plasma semaglutide and liraglutide concentrations are based on their circulating half-lives and thus are theoretical.
case_images: luac004f1.jpg
case_images: PMC10578406_01_luac004f1.jpg
case_images: luac004-F1
case_images: This pattern repeated itself for the next 3 injections (ie, positive effect of semaglutide 2 days after administration and then reappearance of BAD symptoms on day 4 after injection) (Fig. 1).